Newsroom

Sorted by: Latest

-

Agilent Completes Acquisition of Proscia

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Proscia®, a leading provider of digital-pathology software for clinical and life-sciences customers. Under the terms of the transaction, Agilent acquired Proscia for $240 million in cash at closing, with up to an additional $30 million payable based on the achievement of future performance milestones. Following the closing of the transact...
-

Integrated Private Wealth Expands Leadership and Advisory Team With Four Strategic Appointments

GIG HARBOR, Wash.--(BUSINESS WIRE)--Integrated Partners (“Integrated”), a national financial planning and registered investment advisory (RIA) firm serving more than $30 billion in assets under advisement (AUA), today announced that Integrated Private Wealth (“IPW”), its private wealth firm focused on serving business owners and their families, has expanded its leadership and advisory team with three new appointments and one internal promotion. The appointments include Ron Bowker as chief of st...
-

NATIXIS UK Regulatory Announcement: Form 8.3 Segro plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

NATIXIS UK Regulatory Announcement: Form 8.3 Rotork plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

Penguin Solutions Announces Agreement to Sell Cree LED to Transom Capital Group

FREMONT, Calif.--(BUSINESS WIRE)--Penguin Solutions, Inc. (“Penguin Solutions,” “Penguin,” or the “Company”) (Nasdaq: PENG), the AI Factory Platform Company, today announced that it has entered into a definitive agreement to sell its Cree LED business (“Cree LED”) to Transom Capital Group (“Transom”), a leading operations-focused middle-market private equity firm. The planned divestiture reflects Penguin Solutions’ commitment to creating long-term shareholder value. It will further align the Co...
-

As AI Use Grows, New Report from Evotix and What Works Institute Reveals Changing EHS Priorities and New Challenges

CHICAGO & MANCHESTER, England--(BUSINESS WIRE)--2027 Risk Recalibrated report finds expanding AI use alongside gaps in EHS capacity, human oversight and measurement...
-

Bubbies Ice Cream Brings Back Fan-Favorite Peppermint Bark Drizzled Mochi Ice Cream for the Holiday Season

PHOENIX--(BUSINESS WIRE)--Bubbies Ice Cream Brings Back Fan-Favorite Peppermint Bark Drizzled Mochi Ice Cream for the Holiday Season...
-

NATIXIS UK Regulatory Announcement: Form 8.3 Mitie Group plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced the presentation of initial first-in-human clinical data from the ongoing Phase 1 study of IM-1021, an investigational ROR1-targeted antibody-drug conjugate (ADC) for the treatment of advanced B-cell lymphomas, at the 68th American Society of Hematology (ASH) Annual Meeting. The poster will include i...
-

New Study Finds AI Adoption Surging Across Go-to-market Teams, but Revenue Gains Lag Behind

SAN DIEGO--(BUSINESS WIRE)--New Harvard Business Review Analytic Services research, sponsored by Seismic, reveals opportunities for significant AI upside in revenue enablement....